INTERVIEW: Gail Simone Guides 'Blockbuster Update' of Red Sonja, Vampirella and Dejah Thoris
Called, fittingly enough, Action Presidents, the new title begins at the beginning, with a look at George Washington “in the hilarious-but-accurate manner of their previous works,” Action Philosophers and The Comic Book History of Comics.
“Long-announced, finally arrived, Action Presidents will profile a different chief executive in each issue,” Van Lente said in a statement, “at least until we start getting to the really lame ones.”
Each issue will be available for $1.99 on comiXology, “with a special dead tree edition available through distributor Tony Shenton and at conventions.” They plan to publish a collected edition once five or six issues have been released.
In a timely addendum, Evil Twin Comics confirmed in a press release its commitment to remaining in New York City, “specifically beneath a bridge spanning the Gowanus Canal.” Check out a preview of Action Presidents #1 below.
To see what Tom and the Robot 6 crew have been read, click the link below.
Welcome to Food or Comics?, where every week we talk about what comics we’d buy at our local comic shop based on certain spending limits — $15 and $30 — as well as what we’d get if we had extra money or a gift card to spend on a “Splurge” item.
If I had $15:
I’d pick up Batman Inc. #7 ($2.99) and that would be it, so afterwards I’d pat myself on the back for not blowing my whole $15.
If I had $30:
I’d go with Farm 54 ($25), a new hardbound collection of stories by the brother and sister team of Galit and Gilad Seliktar, courtesy of Fanfare/Ponent Mon. It’s basically a semi-autobiographical collection of tales capturing a young woman at various critical stages in her youth, adolescence and young adulthood, all done in a tentative, wispy watercolor. Lovely stuff to flip through, at the very least.
Fred Van Lente is hellbent on getting his name on the cover of every Marvel comic, or so it would seem. I could try to list all the Marvel titles he has written, is writing or will be writing, but we’d never get to the actual interview. Suffice to say that Marvel keeps him busy. And then there’s Action Philosophers (Van Lente’s successful independent collaboration with artist Ryan Dunlavey). Back to Marvel, this week marks the start of his Spider-Man/Chameleon storyline with the release of Amazing Spider-Man 602. Here’s the official word on Van Lente–he “is the New York Times bestselling author of Incredible Hercules (with Greg Pak) and Marvel Zombies 3, as well as the American Library Association award-winning Action Philosophers. His other comics incldue Comic Book Comics, MODOK’s 11, X Men Noir and Amazing Spider-Man.” Van Lente was kind enough to do an email interview with me about his various projects.
Tim O’Shea: Marvel is clearly pleased with X-Men Noir, given that they have announced a follow-up with the same team, Mark Of Cain. Given that a great deal of your writing for Marvel is within the “main” Marvel U, how liberating is at as a writer to get to play around with characters in a Noir universe?
Fred Van Lente: I always like to have big, bloody Grand Guignol endings, with bodies heaped up on stage like at the end of a Shakespeare tragedy. Nothing says “dramatic climax” like “everybody dies.” One of the nice things about working with the X-Men franchise in the Noirverse is that it has so many characters there are always some left over no matter how many you knock off. XMN1 we whacked Jean Grey, Magneto, Mastermind, Blob, Unus, Beast, Banshee, Rogue, Iceman, Gambit and Qucksilver, but we still had Wolverine, Puck, Cyclops, Angel, Professor X, and the Scarlet Witch to kick around.
In Mark of Cain they’ll be joined by a large bulk of the “All-New, All-Different” cast, including Noir analogues of Juggernaut (obviously), Emma Frost, Nightcrawler, Storm, and Colossus, and a few surprise appearances as well.
We’ve already been asked about a third installment, so my co-creator Dennis Calero and I will have to be careful not to kill everybody off. Even the X-Men have their limits in terms of mortality.